Healthcare Review: Cytori Therapeutics, Savient Pharmaceuticals, Questcor Pharmaceuticals, Peregrine Pharmaceuticals Are Big Movers Print
By Staff and Wire Reports   
Friday, 28 September 2012 13:01
U.S. stocks retreated on Friday after investors sold shares to lock in gains at the end of equities' robust third quarter and as Spanish banks' stress tests were mostly within expectations.

An independent audit of Spain's 14 main banks showed they had 59.3 billion euros ($76.3 billion) in extra capital to ride out a serious economic downturn, nearly matching expectations. Several healthcare stocks are making notable news at mid day on Friday.

Cytori Therapeutics Inc. (USA)(NASDAQ:CYTX)
shares jumped 16.32% to $4.49 after the company announced that it has been awarded a contract that may be valued up to $106 million by the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA), if all Contract Options are executed. The Contract is for preclinical and clinical development of the Company’s cell therapy for the treatment of thermal burns combined with radiation injury.

Savient Pharmaceuticals, Inc.(NASDAQ:SVNT)
stock gained 6.73% to $2.38. The company announced that the appointment of John P. Hamill as Senior Vice President & Chief Financial Officer (CFO )effective from September 24, 2012. Hamill will be responsible for all financial and accounting functions of the company and will report directly to Lou Ferrari, President and Chief Executive Officer of Savient.

Nymox Pharmaceutical Corporation(NASDAQ:NYMX)
shares increased 3.46% to $6.58 in the morning hour. The company, on Sept. 20, announced that the Independent Data Monitoring Committee for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) has reported a positive interim safety analysis of clinical data from the first group of patients to receive either a high or low dose of NX-1207 for treatment of their localized prostate cancer.

Questcor Pharmaceuticals, Inc.(NASDAQ:QCOR)
shares increased 3.42% to $18.45 after the company announced that its Board of Directors has adopted a policy to pay a regular quarterly dividend in such amounts as the Board of Directors may determine from time to time. The Board of Directors has declared an initial quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on October 31, 2012. The initial dividend will be paid on or about November 15, 2012.

Peregrine Pharmaceuticals (NASDAQ:PPHM)
stock dropped 7.21% to $1.03 after the company announced that it has been chosen by Advanced BioScience Laboratories, Inc. (ABL) to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein, as a component of a preventive vaccine against HIV infection.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus